Lumentum vs Novavax Inc — how do they compare? Lumentum trades at $1,104.5 (market cap $94.99B), while Novavax Inc trades at $12.77 (market cap $1.82B). The key difference: Lumentum is far larger — about 52.2× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 4,855,776). Which is the better fit depends on your goals — on Pluang, investors hold Lumentum for 4 Days and Novavax Inc for 59 Days on average.
| LITE | NVAX | |
|---|---|---|
Market Cap | $94.99B | $1.82B |
Volume | 4,855,776 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $1.13K | $12.56 |
52-Week Low | $149.61 | $6.22 |
Typical Hold Time | 4 Days | 59 Days |
Enterprise Value | $93.92B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →